A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (NCT03673501)
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
🩺 Plain-English Summary (8th-Grade Level)
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Scottsdale — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (121 Sites)
Showing the first 25 of 121 sites.
- Mayo Clinic Scottsdale — Scottsdale, Arizona
- University of California San Diego Medical Center — La Jolla, California
- UCLA Hematology Oncology Center - Main Site — Los Angeles, California
- Stanford Medicine — Stanford, California
- University of Colorado Hospital - Anschutz Cancer Pavillion — Aurora, Colorado
- Rocky Mountain Cancer Centers — Denver, Colorado
- Smilow Cancer Hospital at Yale — New Haven, Connecticut
- Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Mayo Clinic Florida — Jacksonville, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
- Orlando Health UF Health Cancer Center — Orlando, Florida
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute — Atlanta, Georgia
- Georgia Cancer Specialists — Sandy Springs, Georgia
- Northwestern Memorial Hospital — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
- IU Simon Cancer Center — Indianapolis, Indiana
- University of Iowa Hospital and Clinics — Iowa City, Iowa
- Norton Cancer Institute, Audubon Hospital Campus — Louisville, Kentucky
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- University of Minnesota Medical Center-Fairview — Minneapolis, Minnesota
- Mayo Clinic — Rochester, Minnesota
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Stromal Tumors
- SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST — Miami, Florida
- Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. — Houston, Texas
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST — Miami, Florida
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor — La Jolla, California
- Imatinib TDM in GIST — Lexington, Kentucky
Explore by condition: All Gastrointestinal Stromal Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.